- Policy
- SK's Cosca 25mg was first approved
- by Lee, Tak-Sun Apr 15, 2021 05:56am
- SK Chemical introduces generic for Losartan 25mg earlier than the original. At one time, SK Chemicals had the experience of selling delegated generics of the original Cozaar, so it is drawing attention. On the 14th, the MFDS approved SK Chemical's Cosca25mg (Losartan potassium). Losartan potassium 25mg has been widely used, but it has not
- Company
- Measures for the reimbursement of advanced therapies
- by Apr 15, 2021 05:56am
- The release of the CAR-T treatment ‘Kymriah (tisagenlecleucel)’ in Korea was met with both anticipation and concerns. The drug itself is undeniably an innovative drug that can offer new opportunities to blood cancer patients with short life expectancy. However, the challenge lies in how this innovative new drug that costs 500 million won per d
- Policy
- Moderna's COVID-19 vaccine has been applied for approval
- by Lee, Tak-Sun Apr 15, 2021 05:56am
- Moderna's COVID-19 vaccine has begun to be approved in Korea. If Moderna vaccine is approved, it will be the fourth vaccine after AstraZeneca, Pfizer and Janssen vaccines. The MFDS announced on the 12th that GC Pharma has applied for approval as an import item for COVID-19 vaccine from Moderna in the US. Moderna vaccine is one of the va
- Opinion
- [Reporter's view] Expensive vaccine sovereignty
- by Apr 15, 2021 05:56am
- The cervical cancer vaccine is Gardasil 9, and the rotavirus vaccines RotaTeq and Rotarix. Vaccines that are considered essential vaccinations, but consumers are less accessible. Foreign pharmaceutical companies are raising prices all at once. Gardasil 9 and RotaTeq's supply prices rose by 15% and 17%, respectively, from this month. RotaTeq
- Company
- “The framework to list ultra-expensive new drugs exists"
- by Eo, Yun-Ho Apr 14, 2021 06:07am
- We are living in an era where a single injection may completely cure cancer. The catch is that the 'single dose' would cost 500 million won. Such ultra-expensive advanced new drugs are not an item of our dreams &8211; it is already within our reach. In addition to the CAR-T (Chimeric Antigen Receptor T cells) therapy Kymriah (tisagenlecleuce
- Company
- Generic for Eliquis, stop selling after supreme court loss
- by Kim, Jin-Gu Apr 14, 2021 06:07am
- Eliquis (Apixaban)’s generic companies stop selling one after another. This is a strategy after the Supreme Court ruled in favor of the original company BMS in the Eliquis patent dispute. This is a measure to reduce the risk even a little in preparation for future lawsuits for claiming damages. According to the pharmaceutical industry
- Policy
- NHIS and choline alfoscerate makers fail to reach agreement
- by Kim, Jung-Ju Apr 14, 2021 06:06am
- Negotiations on the retrieval of health insurance benefits paid for 60 choline alfoscerate products have all fell through despite the series of extensions made on its negotiation period. The key cause of the negotiation breakddown was that the payer, National Health Insurance Service (NHIS), and the pharmaceutical companies were unable t
- Policy
- MFDS to support domestic vaccine for COVID-19
- by Lee, Tak-Sun Apr 14, 2021 06:06am
- The MFDS has announced that it will establish a new indicator that eases the phase 3 clinical criteria for the existing COVID-19. Through this, the plan is to support the rapid commercialization of domestically developed vaccines. Director Kang-rip Kim made such a statement at a briefing at the special quarantine inspection meeting i
- Company
- Geo-Young is interested in distributing botulinum products
- by Nho, Byung Chul Apr 14, 2021 06:06am
- Geo-Young and Zuellig entered the competition for the storage and distribution of Xeomin of Multz, Germany, which is the best importer of botulinum toxin products. According to the pharmaceutical industry on the 9th, Multz is conducting a competitive bidding ahead of the expiration of the contract with Zuellig, an existing Xeomin storage
- Company
- MNC employees earn ₩91 million on average
- by An, Kyung-Jin Apr 13, 2021 05:19pm
- GSK Consumer Healthcare Korea employees received on average a salary of 150 million won last year. Employees at GSK Korea, Boehringer Ingelheim Korea, Sanofi Pasteur, Viatris Korea, Kyowa Kirin Korea, Galderma Korea, Pfizer Korea, and Abbvie Korea also received an average salary of over 100 million won. According to the Financial Super
